Seven Fleet Capital Management LP Makes New Investment in Athira Pharma, Inc. $ATHA

Seven Fleet Capital Management LP acquired a new position in shares of Athira Pharma, Inc. (NASDAQ:ATHA) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 127,951 shares of the company’s stock, valued at approximately $969,000. Athira Pharma makes up about 0.7% of Seven Fleet Capital Management LP’s portfolio, making the stock its 25th largest position. Seven Fleet Capital Management LP owned approximately 3.24% of Athira Pharma as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Focus Partners Wealth purchased a new position in shares of Athira Pharma in the third quarter valued at $35,000. Jane Street Group LLC bought a new position in Athira Pharma during the fourth quarter valued at $100,000. Renaissance Technologies LLC grew its stake in shares of Athira Pharma by 44.7% in the 4th quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock worth $569,000 after buying an additional 23,223 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Athira Pharma in the 4th quarter worth about $2,456,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Athira Pharma in the 4th quarter worth about $2,891,000. 57.12% of the stock is currently owned by institutional investors.

Athira Pharma Trading Down 4.5%

Shares of NASDAQ ATHA opened at $8.22 on Friday. Athira Pharma, Inc. has a 12-month low of $0.23 and a 12-month high of $8.36. The firm’s 50-day moving average price is $9.33 and its 200-day moving average price is $7.44. The stock has a market capitalization of $32.42 million, a price-to-earnings ratio of -0.85 and a beta of 2.79.

Athira Pharma Company Profile

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.